Monte Rosa Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Monte Rosa Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.63M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($72.70M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($135.35M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($108.50M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($73.96M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($35.88M) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($54.21M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($81.11M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($143.31M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($112.38M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($72.88M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($28.01M) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.50M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $121.56M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $111.27M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $85.06M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $57.16M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $24.01M | Mar 29, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.80M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $42.00M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($43.80M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($92.47M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($59.36M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($23.05M) | Mar 29, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.70M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.99M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $19.04M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $12.91M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $9.73M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.39M | Mar 29, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.66M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $438.73M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $303.76M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $342.39M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $366.33M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $49.38M | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $215.60M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $215.80M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $124.51M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $70.98M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $18.81M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $30.34M | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.06M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $222.94M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $179.25M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $271.41M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $347.52M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($48.73M) | Mar 16, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($477.21M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($438.59M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($365.89M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($230.54M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($122.04M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($48.08M) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.88M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $224.25M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $128.10M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $54.91M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $346.07M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $41.70M | Mar 29, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 65.54M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 61.51M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 50.14M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 49.32M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 46.54M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 1.69M | Mar 29, 2022 |